摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-甲基-3-硝基苯硼酸频那醇酯 | 910235-64-2

中文名称
2-甲基-3-硝基苯硼酸频那醇酯
中文别名
2-甲基-3-硝基苯基硼酸,频哪醇酯;2-甲基-3-硝基苯基硼酸频哪醇酯
英文名称
4,4,5,5-tetramethyl-2-(2-methyl-3-nitrophenyl)-1,3,2-dioxaborolane
英文别名
2-(2-methyl-3-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
2-甲基-3-硝基苯硼酸频那醇酯化学式
CAS
910235-64-2
化学式
C13H18BNO4
mdl
——
分子量
263.101
InChiKey
DGUVYVUSWYNPNM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    364.4±35.0 °C(Predicted)
  • 密度:
    1.13±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    19
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    64.3
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:266996edbe0f8370ab6b323e24fedba0
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Methyl-3-nitrophenylboronic acid, pinacol ester
Synonyms: 4,4,5,5-Tetramethyl-2-(2-methyl-3-nitrophenyl)-1,3,2-dioxaborolane

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-Methyl-3-nitrophenylboronic acid, pinacol ester
CAS number: 910235-64-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H18BNO4
Molecular weight: 263.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

反应信息

  • 作为反应物:
    参考文献:
    名称:
    氨基和羟甲基苯并恶唑硼酸酯的合成:进一步功能化的著名支架
    摘要:
    本文描述了一种短,简单而有效的合成氨基和羟甲基取代的苯并氧杂硼酸的方法的开发。关键步骤是通过苯胺的硼化使硼早期掺入。然后将形成的硼酸盐分两步精加工成最终产品,收率很高。
    DOI:
    10.1002/ejoc.201900013
  • 作为产物:
    描述:
    N-(2-methyl-3-nitrophenyl)boranyl-N-propan-2-ylpropan-2-amine 以 乙醚 为溶剂, 反应 5.0h, 生成 2-甲基-3-硝基苯硼酸频那醇酯
    参考文献:
    名称:
    在温和条件下使用IV类茂金属进行硼酰化
    摘要:
    芳香重氮盐的硼酸酯化反应已使用钛茂和锆茂衍生物作为催化剂进行了优化。该反应使用二异丙基氨基硼烷作为硼化剂,并在室温下平稳进行,以在甲醇解和频哪醇酯交换后提供芳基硼酸酯。已经发现反应机理是通过自由基途径进行的。
    DOI:
    10.1016/j.tetlet.2014.01.080
点击查看最新优质反应信息

文献信息

  • BTK INHIBITOR
    申请人:Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
    公开号:US20170313683A1
    公开(公告)日:2017-11-02
    Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV).
    提供了一系列的BTK抑制剂,特别公开了一种由公式(I)、(II)、(III)或(IV)表示的化合物、药用可接受的盐、互变异构体或前药。
  • CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF
    申请人:BLOMGREN Peter A.
    公开号:US20090082330A1
    公开(公告)日:2009-03-26
    Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
    公式I的化合物能够抑制Btk,本文中对此进行了描述。描述了包含至少一个公式I化合物的药物组合物,以及至少一个从载体、佐剂和辅料中选择的药用辅料。描述了治疗患有对Btk活性抑制和/或B细胞活性有反应的某些疾病患者的方法。还描述了用于确定样本中存在Btk的方法。
  • [EN] NOVEL IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES<br/>[FR] DÉRIVÉS INNOVANTS D'IMIDAZO[1,2-A]PYRIDINE ET D'IMIDAZO[1,2-B]PYRIDAZINE
    申请人:HOFFMANN LA ROCHE
    公开号:WO2009077334A1
    公开(公告)日:2009-06-25
    Imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives which inhibit Btk and are useful for the treatment of auto-immune and inflammatory diseases caused by aberrant B-cell activation, e.g. arthritis.
    咪唑[1,2-a]吡啶和咪唑[1,2-b]吡嗪衍生物抑制Btk,对于治疗由异常B细胞活化引起的自身免疫和炎症性疾病,如关节炎,具有益处。
  • [EN] PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF<br/>[FR] PYRIDINONES/PYRAZINONES, LEUR PROCÉDÉ DE FABRICATION ET LEUR MÉTHODE D'UTILISATION
    申请人:GILEAD CONNECTICUT INC
    公开号:WO2012031004A1
    公开(公告)日:2012-03-08
    Pyridone and pyrazinone compounds of Formula (I) including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Formula (I)中的吡啶酮和吡嗪酮化合物,包括其立体异构体、互变异构体和药学上可接受的盐,用于抑制Btk激酶,并用于治疗由Btk激酶介导的炎症等免疫紊乱。公开了使用Formula I化合物进行哺乳动物细胞中的体外、体内和体内诊断以及治疗此类疾病或相关病理条件的方法。
  • Iron-Catalysed Borylation of Arenediazonium Salts to Give Access to Arylboron Derivatives<i>via</i>Aryl(amino)boranes at Room Temperature
    作者:Ludovic D. Marciasini、Nicolas Richy、Michel Vaultier、Mathieu Pucheault
    DOI:10.1002/adsc.201200942
    日期:2013.4.15
    Complementary to previously described Miyaura borylation methods, a new access to boron derivatives via aryl(amino)boranes is described. Direct coupling between aryldiazonium salts and diisopropylaminoborane is catalysed by 0.1% ferrocene leading to the formation of a carbon‐boron bond. The obtained aryl(amino)boranes could eventually then be transformed into boronic acids, boronates or borates.
    作为对前述Miyaura硼化方法的补充,描述了通过芳基(氨基)硼烷获得硼衍生物的新途径。0.1%的二茂铁催化芳基重氮盐与二异丙基氨基硼烷之间的直接偶合,导致形成碳硼键。然后最终可以将获得的芳基(氨基)硼烷转化为硼酸,硼酸酯或硼酸酯。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐